Evidence map›Paper›PMID 38499702›Full record

ArticleBasic research in cardiology2024

Oxidation-reduction imaging of myoglobin reveals two-phase oxidation in the reperfused myocardium.

Sally Badawi, Clémence Leboullenger, Matthieu Chourrout, Yves Gouriou, Alexandre Paccalet, Bruno Pillot, Lionel Augeul, Radu Bolbos, Antonino Bongiovani, Nathan Mewton and 7 more

Open access · hybridAbstract read
In one paragraph

Article in Basic research in cardiology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact, top 95% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 0 citations in OpenAlex.

  1. N-International journal of molecular sciences · 2026
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

17 authors at 9 institutions in 2 countries.

Sally BadawiUniv-Lyon, CarMeN Laboratory, Inserm U1060, INRAE U1397, Université Claude Bernard Lyon 1, 69550, Bron, France.
Clémence LeboullengerUniv. Lille, CNRS, Inserm, Institut Pasteur de Lille, US 41-UAR 2014-PLBS, CHU Lille, 59000, Lille, France.
Matthieu ChourroutUniv-Lyon, CarMeN Laboratory, Inserm U1060, INRAE U1397, Université Claude Bernard Lyon 1, 69550, Bron, France.
Yves GouriouUniv-Lyon, CarMeN Laboratory, Inserm U1060, INRAE U1397, Université Claude Bernard Lyon 1, 69550, Bron, France.
Alexandre PaccaletUniv-Lyon, CarMeN Laboratory, Inserm U1060, INRAE U1397, Université Claude Bernard Lyon 1, 69550, Bron, France.
Bruno PillotUniv-Lyon, CarMeN Laboratory, Inserm U1060, INRAE U1397, Université Claude Bernard Lyon 1, 69550, Bron, France.
Lionel AugeulUniv-Lyon, CarMeN Laboratory, Inserm U1060, INRAE U1397, Université Claude Bernard Lyon 1, 69550, Bron, France.
Radu BolbosCERMEP-Imagerie du Vivant, Lyon, France.
Antonino BongiovaniUniv. Lille, CNRS, Inserm, Institut Pasteur de Lille, US 41-UAR 2014-PLBS, CHU Lille, 59000, Lille, France.
Nathan MewtonUniv-Lyon, CarMeN Laboratory, Inserm U1060, INRAE U1397, Université Claude Bernard Lyon 1, 69550, Bron, France.
Thomas BochatonUniv-Lyon, CarMeN Laboratory, Inserm U1060, INRAE U1397, Université Claude Bernard Lyon 1, 69550, Bron, France.
Michel OvizeUniv-Lyon, CarMeN Laboratory, Inserm U1060, INRAE U1397, Université Claude Bernard Lyon 1, 69550, Bron, France.
Meryem TardivelUniv. Lille, CNRS, Inserm, Institut Pasteur de Lille, US 41-UAR 2014-PLBS, CHU Lille, 59000, Lille, France.
Mazen KurdiLaboratory of Experimental and Clinical Pharmacology, Department of Chemistry and Biochemistry, Doctoral School of Sciences and Technology, Faculty of Sciences, Lebanese University, Beirut, Lebanon.
Emmanuelle Canet-SoulasUniv-Lyon, CarMeN Laboratory, Inserm U1060, INRAE U1397, Université Claude Bernard Lyon 1, 69550, Bron, France.
Claire Crola Da SilvaUniv-Lyon, CarMeN Laboratory, Inserm U1060, INRAE U1397, Université Claude Bernard Lyon 1, 69550, Bron, France.
Gabriel BidauxUniv-Lyon, CarMeN Laboratory, Inserm U1060, INRAE U1397, Université Claude Bernard Lyon 1, 69550, Bron, France. gabriel.bidaux@univ-lyon1.fr.
Université Claude Bernard Lyon 1 · FRLaboratoire CarMeN · FRCentre Hospitalier Universitaire de Lille · FRHospices Civils de Lyon · FRInserm · FRCentre d'Exploration et de Recherche Médicale par Emission de Positons · FRCentre National de la Recherche Scientifique · FRInstitut National de Recherche pour l'Agriculture, l'Alimentation et l'Environnement · FRLebanese University · LB

Funding

Agence Nationale de la Recherche ANR-10-IBHU-004Agence Nationale de la Recherche ANR-16-RHUS- 0009
6 · The paper itself

Abstract

Myocardial infarction (MI) is a serious acute cardiovascular syndrome that causes myocardial injury due to blood flow obstruction to a specific myocardial area. Under ischemic-reperfusion settings, a burst of reactive oxygen species is generated, leading to redox imbalance that could be attributed to several molecules, including myoglobin. Myoglobin is dynamic and exhibits various oxidation-reduction states that have been an early subject of attention in the food industry, specifically for meat consumers. However, rarely if ever have the myoglobin optical properties been used to measure the severity of MI. In the current study, we develop a novel imaging pipeline that integrates tissue clearing, confocal and light sheet fluorescence microscopy, combined with imaging analysis, and processing tools to investigate and characterize the oxidation-reduction states of myoglobin in the ischemic area of the cleared myocardium post-MI. Using spectral imaging, we have characterized the endogenous fluorescence of the myocardium and demonstrated that it is partly composed by fluorescence of myoglobin. Under ischemia-reperfusion experimental settings, we report that the infarcted myocardium spectral signature is similar to that of oxidized myoglobin signal that peaks 3 h post-reperfusion and decreases with cardioprotection. The infarct size assessed by oxidation-reduction imaging at 3 h post-reperfusion was correlated to the one estimated with late gadolinium enhancement MRI at 24 h post-reperfusion. In conclusion, this original work suggests that the redox state of myoglobin can be used as a promising imaging biomarker for characterizing and estimating the size of the MI during early phases of reperfusion.

Indexed as

Myocardial InfarctionMyocardial Reperfusion InjuryMyocardiumMyoglobinOxidation-ReductionAnimalsDisease Models, AnimalMicroscopy, ConfocalMicroscopy, FluorescenceMyoglobinAutofluorescenceClarityHeartMyocardial infarctionOxidation

Identifiers

PMID38499702
PMCPMC11142982
OpenAlexW4392928092

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.